Skip to main content
Premium Trial:

Request an Annual Quote

Ortho-McNeil Pharma Licenses Additional Component of Cellzome s Alzheimer Program

NEW YORK, May 23 (GenomeWeb News) - Ortho-McNeil Pharmaceutical has licensed another part of Cellzome's proteomics-based Alzheimer's disease program, exercising an option under the terms of a collaboration signed between the two companies in March, Cellzome said today.


Cellzome will receive an additional access fee for its proteomics technology and continued research funding. Johnson & Johnson Pharmaceutical Research and Development, an affiliate of Ortho-McNeil, will continue to provide research support.


The gamma secretase modulator program licensed by Ortho-McNeil includes small molecules for development as oral drugs for the treatment of Alzheimer's disease.

The Scan

Study Finds Sorghum Genetic Loci Influencing Composition, Function of Human Gut Microbes

Focusing on microbes found in the human gut microbiome, researchers in Nature Communications identified 10 sorghum loci that appear to influence the microbial taxa or microbial metabolite features.

Treatment Costs May Not Coincide With R&D Investment, Study Suggests

Researchers in JAMA Network Open did not find an association between ultimate treatment costs and investments in a drug when they analyzed available data on 60 approved drugs.

Sleep-Related Variants Show Low Penetrance in Large Population Analysis

A limited number of variants had documented sleep effects in an investigation in PLOS Genetics of 10 genes with reported sleep ties in nearly 192,000 participants in four population studies.

Researchers Develop Polygenic Risk Scores for Dozens of Disease-Related Exposures

With genetic data from two large population cohorts and summary statistics from prior genome-wide association studies, researchers came up with 27 exposure polygenic risk scores in the American Journal of Human Genetics.